ArticleMovement disorders clinical practice2025
How Early Does Anosognosia Begin in Huntington's Disease?
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unawareness of motor deficit in Huntington's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with Huntington's disease (HD) commonly experience anosognosia, a lack of awareness of disease-specific deficits. However, how early anosognosia begins in the course of HD remains unclear.
objectiveTo characterize the onset of anosognosia in HD by exploring its presence/absence at various stages of disease.
methodsThe Anosognosia Scale was given to 60 gene carriers (stratified by the HD Integrated Staging System (HD-ISS), Total Functional Capacity (TFC), CAG-Age-Product (CAP), and composite UHDRS (cUHDRS) score) as well as their study partners. Differences between informant and patient scores of ≥6 points were considered evidence of anosognosia.
results18% of participants in HD-ISS stage 0/1, 22% with TFC = 13, 37% who would be eligible for clinical trials (CAP score 400-500), and 23% with a cUHDRS ≥14 displayed anosognosia.
conclusionsWe conclude that anosognosia appears early in HD. This lack of awareness should dissuade against over-reliance on self-report instruments in HD clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.